Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > GeneSegues Announces Allowance in Europe of New Patent Broadly Covering Targeted Drug Delivery At Sub-50 Nanometer Scale: Notification of “Intent to Grant” for Nanocapsule Composition and Methods

Abstract:
GeneSegues, Inc., a leader in drug delivery at the sub-50 nanometer scale, announced today that the European Patent Office (EPO) has issued a notification of intent to grant for a patent covering the company's proprietary drug delivery technology (EP Application No. 01920161.5). This patent stems from pioneering work by the company in delivering therapeutic molecules such as oligonucleotides and plasmid DNA to target cells using nanocapsules of less than 50 nanometers in diameter. Compositions of this size impart significant advantages including entering the target cell without triggering defense mechanisms that can degrade the capsule and drug.

GeneSegues Announces Allowance in Europe of New Patent Broadly Covering Targeted Drug Delivery At Sub-50 Nanometer Scale: Notification of “Intent to Grant” for Nanocapsule Composition and Methods

Minneapolis, MN | Posted on March 6th, 2012

"We are gratified that the EPO has recognized the importance and patentability of our discoveries in nonviral technologies that can take advantage of efficient lipid raft pathways into the target cell," said Gretchen Unger, Ph.D., Chief Scientific Officer and founder of GeneSegues. "This patent covers a broad and significant technology platform which we are continuing to develop with collaborators across a range of applications including cancer, liver, and infectious diseases."

The new patent includes claims covering compositions of sub-50 nanometer capsules and methods of formulation. The composition claims cover sub-50 nanometer capsules that consist of a substitutable biopolymer ligand shell which can actively target the composition to any desired cell type, and can encapsulate large or small molecule drug cargo. The method claims cover the processes for formulating the nanocapsules with a novel design that is both versatile and scalable.

####

About GeneSegues, Inc.
GeneSegues is a biopharmaceutical company focused on applying its novel drug delivery technology to produce breakthrough nucleic acid-based therapeutics and vaccines for the treatment and prevention of serious diseases. The company’s sub-50 nanometer (‘s50’) capsule technology addresses the series of biological barriers that prevent nucleic acids from reaching the therapeutically-important cytoplasm and nucleus of the target cell.

For more information, please click here

Contacts:
Gretchen Unger, Ph.D.
Chief Scientific Officer
GeneSegues, Inc.
952.443.3798

Copyright © GeneSegues, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Flexible electronics integrated with paper-thin structure for use in space January 17th, 2025

‘Brand new physics’ for next generation spintronics: Physicists discover a unique quantum behavior that offers a new way to manipulate electron-spin and magnetization to push forward cutting-edge spintronic technologies, like computing that mimics the human brain January 17th, 2025

Quantum engineers ‘squeeze’ laser frequency combs to make more sensitive gas sensors January 17th, 2025

How a milk component could eliminate one of the biggest challenges in treating cancer and other disease, including rare diseases: Nebraska startup to use nanoparticles found in milk to target therapeutics to specific cells January 17th, 2025

Nanomedicine

How a milk component could eliminate one of the biggest challenges in treating cancer and other disease, including rare diseases: Nebraska startup to use nanoparticles found in milk to target therapeutics to specific cells January 17th, 2025

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery: NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery September 13th, 2024

Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024

Announcements

Quantum engineers ‘squeeze’ laser frequency combs to make more sensitive gas sensors January 17th, 2025

How a milk component could eliminate one of the biggest challenges in treating cancer and other disease, including rare diseases: Nebraska startup to use nanoparticles found in milk to target therapeutics to specific cells January 17th, 2025

The National Space Society Congratulates SpaceX on Starship’s 7th Test Flight: Latest Test of the Megarocket Hoped to Demonstrate a Number of New Technologies and Systems January 17th, 2025

The National Space Society Congratulates Blue Origin on the Inaugural Flight of New Glenn: The Heavy Lift Reusable Rocket Will Open New Frontiers and Provide Healthy Competition January 17th, 2025

Patents/IP/Tech Transfer/Licensing

Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023

Study finds nanomedicine targeting lymph nodes key to triple negative breast cancer treatment: In mice, nanomedicine can remodel the immune microenvironment in lymph node and tumor tissue for long-term remission and lung tumor elimination in this form of metastasized breast cance May 13th, 2022

Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project